Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma

被引：24

作者：

Tachibana, Hidekazu ^{[1
]}

Kondo, Tsunenori ^{[1
]}

Ishihara, Hiroki ^{[2
]}

Fukuda, Hironori ^{[2
]}

Yoshida, Kazuhiko ^{[2
]}

Takagi, Toshio ^{[2
]}

Izuka, Junpei ^{[2
]}

Kobayashi, Hirohito ^{[1
]}

Tanabe, Kazunari ^{[2
]}

机构：

[1] Tokyo Womens Med Univ Med Ctr East, Dept Urol, Tokyo, Japan

[2] Tokyo Womens Med Univ Tokyo, Dept Urol, Tokyo, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 51卷 / 04期

关键词：

anti-programmed death-1 drug; anti-cytotoxic T-lymphocyte-associated protein 4 agent; immunotherapy; papillary renal cell carcinoma; renal neoplasms; SUNITINIB; THERAPY; PD-1;

D O I：

10.1093/jjco/hyaa229

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: Combined immunotherapy of nivolumab plus ipilimumab for intermediate- and poor-risk metastatic clear cell renal cell carcinoma showed prolonged progression-free survival and high objective response rate in a randomized phase III clinical trial. However, the efficacy of this treatment for papillary renal cell carcinoma remains unclear. In the present study, we analysed the efficacy of nivolumab plus ipilimumab therapy for papillary renal cell carcinoma compared with that for clear cell renal cell carcinoma. Materials and Methods: This is a retrospective study of 30 patients with metastatic renal cell carcinoma who received nivolumab and ipilimumab as first-line therapy between December 2015 and May 2020. The objective response rate, progression-free survival and toxicity were compared between the two groups (clear cell renal cell carcinoma and papillary renal cell carcinoma). Results: Out of 30 patients, 7 and 23 were diagnosed with papillary renal cell carcinoma and clear cell renal cell carcinoma, respectively. With a median follow-up of 7.2 months, the median progression-free survival was significantly shorter in papillary renal cell carcinoma than in clear cell renal cell carcinoma (2.4 vs. 28.1 months, P = 0.014). Of the seven patients with papillary renal cell carcinoma, one had partial response, one had stable disease and five had progressive disease, resulting in an objective response rate of 14.2%, which was lower compared to that of clear cell renal cell carcinoma (14.2 vs. 52.1%, P = 0.06). Discontinuation due to toxicity was not observed with papillary renal cell carcinoma, meanwhile 60.8% of patient with clear cell renal cell carcinoma discontinued treatment due to toxicity. Conclusion: Nivolumab plus ipilimumab had modest efficacy for papillary renal cell carcinoma compared with that for clear cell renal cell carcinoma. Nivolumab plus ipilimumab remains an option for a limited number of patients with intermediate- or poor-risk papillary renal cell carcinoma.

引用

页码：646 / 653

页数：8

共 27 条

[1] Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial [J].

Armstrong, Andrew J. ;

Halabi, Susan ;

Eisen, Tim ;

Broderick, Samuel ;

Stadler, Walter M. ;

Jones, Robert J. ;

Garcia, Jorge A. ;

Vaishampayan, Ulka N. ;

Picus, Joel ;

Hawkins, Robert E. ;

Hainsworth, John D. ;

Kollmannsberger, Christian K. ;

Logan, Theodore F. ;

Puzanov, Igor ;

Pickering, Lisa M. ;

Ryan, Christopher W. ;

Protheroe, Andrew ;

Lusk, Christine M. ;

Oberg, Sadie ;

George, Daniel J. .

LANCET ONCOLOGY, 2016, 17 (03) :378-388

[2]

Choueiri TK., 2020, JAMA ONCOL, V6, P1

[3] Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma [J].

Choueiri, Toni K. ;

Vaishampayan, Ulka ;

Rosenberg, Jonathan E. ;

Logan, Theodore F. ;

Harzstark, Andrea L. ;

Bukowski, Ronald M. ;

Rini, Brian I. ;

Srinivas, Sandy ;

Stein, Mark N. ;

Adams, Laurel M. ;

Ottesen, Lone H. ;

Laubscher, Kevin H. ;

Sherman, Laurie ;

McDermott, David F. ;

Haas, Naomi B. ;

Flaherty, Keith T. ;

Ross, Robert ;

Eisenberg, Peter ;

Meltzer, Paul S. ;

Merino, Maria J. ;

Bottaro, Donald P. ;

Linehan, W. Marston ;

Srinivasan, Ramaprasad .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :181-186

[4]

Eble J.N., 2004, PATHOLOGY GENETICS T

[5] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[6] Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features [J].

Geynisman, Daniel M. .

EUROPEAN UROLOGY, 2015, 68 (05) :912-914

[7] Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study [J].

Heng, Daniel Y. C. ;

Xie, Wanling ;

Regan, Meredith M. ;

Warren, Mark A. ;

Golshayan, Ali Reza ;

Sahi, Chakshu ;

Eigl, Bernhard J. ;

Ruether, J. Dean ;

Cheng, Tina ;

North, Scott ;

Venner, Peter ;

Knox, Jennifer J. ;

Chi, Kim N. ;

Kollmannsberger, Christian ;

McDermott, David F. ;

Oh, William K. ;

Atkins, Michael B. ;

Bukowski, Ronald M. ;

Rini, Brian I. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5794-5799

[8] Abscopal effect following nivolumab induction in a patient with metastatic renal cell carcinoma-unique pathological features of the primary specimen: A case report [J].

Hori, Kanta ;

Hirohashi, Yoshihiko ;

Aoyagi, Toshiki ;

Taniguchi, Narumi ;

Murakumo, Masashi ;

Miyata, Haruka ;

Torigoe, Toshihiko ;

Abe, Takashige ;

Shinohara, Nobuo ;

Morita, Ken .

EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 19 (03) :1903-1907

[9] Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma [J].

Ishihara, Hiroki ;

Tachibana, Hidekazu ;

Takagi, Toshio ;

Kondo, Tsunenori ;

Fukuda, Hironori ;

Yoshida, Kazuhiko ;

Iizuka, Junpei ;

Kobayashi, Hirohito ;

Okumi, Masayoshi ;

Ishida, Hideki ;

Tanabe, Kazunari .

TARGETED ONCOLOGY, 2019, 14 (04) :453-463

[10] Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab [J].